X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (280) 280
oncology (266) 266
index medicus (248) 248
female (172) 172
male (160) 160
middle aged (151) 151
aged (148) 148
chemotherapy (119) 119
adult (115) 115
cancer (95) 95
treatment outcome (75) 75
antineoplastic combined chemotherapy protocols - therapeutic use (74) 74
metastasis (71) 71
prognosis (70) 70
settore med/06 - oncologia medica (65) 65
survival (61) 61
antineoplastic agents - therapeutic use (52) 52
aged, 80 and over (50) 50
therapy (49) 49
tumors (48) 48
neoplasm staging (47) 47
colorectal cancer (46) 46
hematology, oncology and palliative medicine (45) 45
disease-free survival (42) 42
care and treatment (41) 41
colorectal neoplasms - drug therapy (39) 39
immunotherapy (36) 36
lung neoplasms - drug therapy (34) 34
neoplasm metastasis (33) 33
analysis (32) 32
hematology (32) 32
patients (32) 32
retrospective studies (32) 32
metastases (31) 31
mutation (31) 31
trial (31) 31
colorectal neoplasms - pathology (30) 30
survival analysis (30) 30
clinical trials (29) 29
lung neoplasms - pathology (29) 29
antineoplastic combined chemotherapy protocols - adverse effects (28) 28
breast cancer (28) 28
respiratory system (27) 27
surgery (27) 27
survival rate (27) 27
carcinoma, non-small-cell lung - drug therapy (26) 26
immunohistochemistry (26) 26
medical prognosis (26) 26
risk factors (26) 26
bevacizumab (25) 25
open-label (25) 25
cancer therapies (24) 24
efficacy (24) 24
research (24) 24
carcinoma (23) 23
double-blind (23) 23
neuroendocrine tumors (23) 23
toxicity (23) 23
angiogenesis (22) 22
drug therapy (22) 22
follow-up studies (22) 22
molecular targeted therapy (22) 22
phase-ii (22) 22
targeted therapy (22) 22
biomarkers (21) 21
carcinoma, non-small-cell lung - pathology (21) 21
fluorouracil (21) 21
kidney neoplasms - drug therapy (21) 21
carcinoma, renal cell - drug therapy (20) 20
colorectal neoplasms - genetics (20) 20
health aspects (20) 20
medicine & public health (20) 20
pharmacology & pharmacy (20) 20
1st-line treatment (19) 19
antineoplastic agents - adverse effects (19) 19
combination (19) 19
drug administration schedule (19) 19
cetuximab (18) 18
cisplatin (18) 18
everolimus (18) 18
lung cancer (18) 18
melanoma (18) 18
phase-iii (18) 18
prospective studies (18) 18
renal cell carcinoma (18) 18
adenocarcinoma (17) 17
combined modality therapy (17) 17
expression (17) 17
gastric cancer (17) 17
kaplan-meier estimate (17) 17
studies (17) 17
sunitinib (17) 17
antineoplastic combined chemotherapy protocols - administration & dosage (16) 16
docetaxel (16) 16
fluorouracil - administration & dosage (16) 16
management (16) 16
radiotherapy (16) 16
resistance (16) 16
antineoplastic agents - administration & dosage (15) 15
capecitabine (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 2017, Volume 552, Issue 7683, pp. 1 - 5
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 883 - 895
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
International Journal of Cancer, ISSN 0020-7136, 07/2019, Volume 145, Issue 2, pp. 576 - 585
Panitumumab is approved for RAS wild‐type metastatic colorectal cancer and was evaluated in Phase III (PRIME, NCT00364013) and Phase II (PEAK, NCT00819780)... 
toxicity | metastatic colorectal cancer | panitumumab | maintenance | epidermal growth factor receptor | survival | 1ST-LINE TREATMENT | BEVACIZUMAB | CHEMOTHERAPY PLUS | PHASE-III TRIAL | NON-INFERIORITY | CETUXIMAB | THERAPY | ONCOLOGY | END-POINTS | KRAS | MUTATIONS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Fluorouracil - therapeutic use | Clinical Trials, Phase III as Topic | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Panitumumab - therapeutic use | Maintenance Chemotherapy | Oxaliplatin - administration & dosage | Retrospective Studies | Bevacizumab - administration & dosage | Treatment Outcome | Randomized Controlled Trials as Topic | Panitumumab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Organoplatinum Compounds - therapeutic use | Clinical Trials, Phase II as Topic | Epidermal growth factor | Metastasis | Consulting services | Analysis | Panitumumab | Colorectal cancer | Toxicity | Colorectal carcinoma | Clinical trials | Diarrhea | Maintenance | Survival | Bevacizumab | Metastases | Confidence intervals | Randomization | Oxaliplatin | Cancer | Index Medicus | Life Sciences | Cancer Therapy and Prevention
Journal Article
Nature Genetics, ISSN 1061-4036, 12/2013, Volume 45, Issue 12, pp. 1470 - 1473
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 810 - 816
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1877 - 1888
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2009, Volume 27, Issue 5, pp. 663 - 671
Journal Article